111
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment

, &
Pages 25-34 | Published online: 21 Feb 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

A. Al-Hillan, R. S. Bajwa, A. Cheema, A. Ezeume, S. Gor, H. Mahida & D. S. Kountz. (2019) Venous thromboembolism prevention through the use of novel Factor Xa inhibitors. Postgraduate Medicine 131:2, pages 89-95.
Read now

Articles from other publishers (7)

Gustavo Lenci Marques, Ana Carolina De Franca, Ana Carolina Saito, Fabiana L Hornung, Ana Carolina Motter, Ana Carolina Falzoni Pontello, Helena Fontana, Juliano Gasparetto & Tiago Zequinão. (2021) Clinical Outcomes and Costs of Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Inpatients: A Cross-Sectional Study. Cureus.
Crossref
Jenna L Snoga, Rebekah M Benitez, Subin Kim, Olivia Creager & Kathleen A Lusk. (2021) A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients. American Journal of Health-System Pharmacy 78:12, pages 1057-1065.
Crossref
Ebrahim Barkoudah, Gregory Piazza, Todd E.H. Hecht, Paul Grant, Steven Deitelzweig, Margaret C. Fang, John Fanikos, Cheng-Kai Kao, Geoffrey D. Barnes, Thomas Chen, Téa Ramishvili, Jeffrey L. Schnipper, Jennifer N. Goldstein, Christian T. Ruff, Scott Kaatz, Aviva Schwartz, Jean M. Connors & Samuel Z. Goldhaber. (2020) Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. The American Journal of Medicine 133, pages 1-27.
Crossref
N. K. Vereina, D. G. Agasyan & V. S. Chulkov. (2020) The risk of venous thromboembolism in patients with heart failure. Russian Journal of Cardiology 25:1, pages 9-13.
Crossref
Reema A. Alshouimi, Shahad M. Al Rammah, Mohammed Y. Alzahrani, Hisham A. Badreldin, Majed S. Al Yami & Omar A. Almohammed. (2019) The use of direct oral anticoagulants for extended duration thromboprophylaxis in medically ill patients: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis 48:3, pages 422-429.
Crossref
Eduardo Vilanova, Bruno C. Vairo, Stephan-Nicollas M. C. G. Oliveira, Bianca F. Glauser, Nina V. Capillé, Gustavo R. C. Santos, Ana M. F. Tovar, Mariana S. Pereira & Paulo A. S. Mourão. (2019) Heparins Sourced From Bovine and Porcine Mucosa Gain Exclusive Monographs in the Brazilian Pharmacopeia. Frontiers in Medicine 6.
Crossref
Alex C. Spyropoulos, Concetta Lipardi, Jianfeng Xu, Wentao Lu, Eunyoung Suh, Zhong Yuan, Bennett Levitan, Chiara Sugarmann, Yoriko De Sanctis, Theodore E. Spiro, Elliot S. Barnathan & Gary E. Raskob. (2019) Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clinical and Applied Thrombosis/Hemostasis 25, pages 107602961988602.
Crossref